Home > Back to Publisher > Report Information

Booming Global Obesity Drug Market

RNCOS
December 1, 2008
80 Pages - SKU: CICQ2043024

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

The price of this report has been reduced due to its age.
“Booming Global Obesity Drug Market”, our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it’s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.

The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi’s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.

The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.

Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China’s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.

Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.

Our report provides forecast on

Global obesity market
Xenical revenue
Meridia revenue
Alli revenue
Global prevalence of obesity
Prevalence of obesity in major developed and emerging markets

Profiling on Key Players

This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.

1. Analyst View
2. The Global Obesity Epidemic: 2.1 Defining Obesity; 2.2 Prevalence of Obesity; 2.3 The Cost of Obesity; 2.4 Obesity is Linked to Higher Rates of Chronic Conditions; 2.5 Obese Spend Significantly Higher on Healthcare
3. Available Weight-loss Techniques & Products: 3.1 Weight-loss Surgery; 3.2 Liposuction; 3.3 Weight-loss Foods & Drinks; 3.4 Diet Centres; 3.5 Weight-loss Drugs
4. Obesity Drugs Market: 4.1 Market Opportunity Assessment; 4.2 Key Weight-loss Drugs; 4.3 Weight-loss Drugs under Clinical Trials
5. Obesity in Developed Markets - A Brief Profile: 5.1 US; 5.2 Japan; 5.3 Germany; 5.4 UK; 5.5 France; 5.6 Italy; 5.7 Spain
6. Obesity in Emerging Markets - A Brief Profile: 6.1 Russia; 6.2 India; 6.3 Brazil; 6.4 China
7. Critical Success Factors: 7.1 Expanding Waistlines; 7.2 High Unmet Needs; 7.3 Self-Consciousness & Fulfillment; 7.4 Strong Pipeline
8. Critical Risk Factors: 8.1 High Failure Rate; 8.2 High Consumer Demand; 8.3 Reimbursement Issues; 8.4 Side Effects
9. Key Company Profiles: 9.1 Abbott Laboratories; 9.2 Roche Holding Ltd; 9.3 Sanofi-Aventis; 9.4 GlaxoSmithKline plc; 9.5 Pfizer Inc.
List of Figures:: Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012; Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012; Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%); Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking; Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%); Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007; Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F; Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007; Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F; Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F; Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008; Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F; Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F; Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F; Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006; Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006; Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006; Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006; Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches
List of Tables:: Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI; Table 3-1: US - Liposuction Statistics (2007); Table 4-1: Alli - Success & Risk Factor Analysis; Table 4-2: Xenical - Success & Risk Factor Analysis; Table 4-3: Acomplia - Success & Risk Factor Analysis; Table 4-4: Meridia - Success & Risk Factor Analysis; Table 4-5: Obesity Drugs in Phase-III Clinical Trials; Table 4-6: Obesity Drugs in Phase-II Clinical Trials; Table 4-7: Obesity Drugs in Phase-I Clinical Trials; Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F); Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F; Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs; Table 9-1: Abbott Laboratories - Strengths & Weaknesses; Table 9-2: Roche Holding Ltd - Strengths & Weaknesses; Table 9-3: Sanofi-Aventis - Strengths & Weaknesses; Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses; Table 9-5: Pfizer Inc. - Strengths & Weaknesses

More Global Obesity Reports

World Market for Gastrointestinal Devices (Rigid, Flexible and Capsule Endoscopes, Bariatric Surgery, Ostomy Products, Enteral Feeding Pumps and Other Devices) by Kalorama Information
This report, The World Market for Gastrointestinal Devices , details the market for endoscopes and other devices used for treating gastrointestinal conditions. There are many factors ...

Bariatric (Obesity) Surgical Devices by Global Industry Analysts
This report analyzes the US and European markets for Bariatric (Obesity) Surgical Devices in US$ Million. The US market is analyzed by the following ...

Anti-Obesity Drugs by Global Industry Analysts
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of ...

Global Obesity Drug Market Analysis by RNCOS
The obesity epidemic has been disseminating among developed countries as well as low-income and middle-income countries. The main factor responsible for the propagation of this ...

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019 by MedMarket Diligence, LLC.
This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report ...

See all reports like this >>

Booming Global Obesity Drug Market

Share this report

Other tasks

Research Assistance

Related Markets

Obesity Reports

Free Alert Me service